recent
year
well
establish
two
major
constitu
part
ubiquitin
proteasom
system
up
proteasom
holoenzym
number
ubiquitin
ligasesplay
crucial
role
viru
replic
also
regul
immunogen
human
immunodefici
viru
type
howev
role
replic
third
major
compon
deubiquitin
enzym
dub
remain
larg
unknown
studi
show
dubinhibitor
di
specif
dub
impair
gag
process
therebi
reduc
infect
releas
virion
without
affect
viral
proteas
activ
furthermor
replic
capac
human
lymphat
tissu
decreas
upon
treatment
inhibitor
without
affect
cell
viabil
strikingli
combinatori
treatment
di
proteasom
inhibitor
synergist
block
viru
replic
concentr
monotreat
ineffect
indic
di
boost
therapeut
effect
proteasom
inhibitor
addit
increas
polyubiquitin
gag
thu
entri
up
major
histocompat
complex
mhc
pathway
summari
data
point
toward
model
specif
inhibitor
dub
interfer
viru
spread
also
increas
immun
recognit
express
cell
homeostasi
eukaryot
cell
maintain
welltun
balanc
biosynthesi
degrad
protein
ubiquitin
proteasom
system
up
constitut
main
nonlysosom
intracellular
protein
degrad
pathway
compris
three
major
compon
proteasom
holoenzym
number
ubiquitin
ligas
broad
varieti
deubiquitin
enzym
dub
ubiquitin
ub
attach
target
protein
cascadelik
catalyt
action
enzym
ubiquitin
molecul
activ
ligas
follow
transfer
one
numer
conjug
enzym
final
ligas
catalyz
transfer
ubiquitin
onto
group
lysin
residu
within
target
protein
review
see
therebi
hela
hela
tzmbl
cell
maintain
dulbecco
modifi
eagl
medium
dmem
contain
vv
inactiv
fetal
calf
serum
fc
mm
lglutamin
uml
penicillin
streptomycin
helak
b
cell
cultiv
dmem
addit
mgml
geneticin
cell
cultur
media
reagent
purchas
gibco
life
technolog
carlsbad
ca
usa
cell
cultur
rpmi
media
supplement
vv
inactiv
fc
mm
lglutamin
uml
penicillin
streptomycin
confluent
monolay
hela
cell
transfect
lipofectamin
life
technolog
accord
manufactur
protocol
twentyfour
hour
post
transfect
cell
lyse
radio
immunoprecipit
assay
ripa
buffer
mm
nacl
mm
trishcl
ph
nadeoxychol
sodium
dodecyl
sulfat
sd
mm
ethylenediaminetetraacet
acid
edta
contain
proteas
inhibitor
cocktail
complet
roch
basel
switzerland
mm
nethylmaleimid
nem
mm
phenylmethylsulfonylfluorid
pmsf
deriv
express
construct
deriv
carri
loop
region
env
construct
harbor
mutat
inactiv
viral
proteas
pr
previous
describ
express
plasmid
encod
codon
optim
synthet
gag
polyprotein
syngag
develop
isol
harbor
wt
mutant
thereof
two
amino
acid
motif
ptap
exchang
aiva
describ
elsewher
construct
contain
ovalbuminderiv
model
epitop
siinfekl
sl
spacer
region
syngagsl
previous
describ
plasmid
express
hemagglutinin
ha
tag
ubiquitin
haub
kindli
provid
hg
describ
elsewher
viru
contain
cell
cultur
supernat
harvest
h
transfect
cell
provir
express
construct
pass
pores
filter
viru
pellet
studi
conduct
accord
declar
helsinki
protocol
approv
ethic
committe
medic
faculti
friedrichalexand
univers
project
identif
code
hela
cell
transient
transfect
wt
overnight
cultiv
c
cell
cultur
supernat
harvest
vlp
releas
supernat
pellet
wv
sucros
centrifug
g
c
min
wash
ice
cold
pb
centrifug
g
c
min
lyse
sdspolyacrylamid
gel
electrophoresi
page
sampl
buffer
contain
sd
boil
min
cell
detach
wash
twice
ice
cold
pb
lyse
ripa
buffer
supplement
mm
pmsf
mm
nem
proteas
inhibitor
cocktail
complet
roch
sampl
analyz
western
blot
protein
band
quantifi
use
aida
hela
cell
transient
transfect
pr
overnight
cultiv
c
releas
vlp
harvest
describ
lyse
proteas
cleavag
buffer
mm
me
ph
nacl
triton
adapt
vitro
process
perform
use
recombin
proteas
protein
abcam
cambridg
uk
h
c
process
termin
addit
sdspage
sampl
buffer
boil
protein
sampl
separ
sdspage
subsequ
transfer
onto
polyvinyliden
fluorid
pvdf
membran
ge
healthcar
littl
chalfont
uk
membran
block
bovin
serum
albumin
incub
appropri
primari
antibodi
ab
gag
detect
rabbit
ab
recogn
ca
seramun
heidese
germani
antibodi
purchas
sigmaaldrich
st
loui
mo
usa
antimous
antirabbit
virus
secondari
antibodi
coupl
horseradish
peroxidas
hrp
obtain
dianova
hamburg
germani
hatag
ubiquitin
visual
use
hareact
monoclon
antibodi
mab
directli
conjug
hrp
roch
hela
cell
lyse
ripa
buffer
contain
proteas
inhibitor
cocktail
nem
pmsf
lysat
adjust
sd
wv
incub
c
min
subsequ
dilut
sd
clear
centrifug
g
min
gag
content
recov
immunoprecipit
antibodi
deriv
patient
sera
prebound
gammabind
plu
sepharos
ge
healthcar
detect
ubiquitin
gag
protein
directli
western
blot
ripa
lysi
buffer
supplement
lactacystin
carbobenzoxylleucineleucineleucin
detect
b
bound
slepitop
cell
stain
allophycocyanin
apc
conjug
mab
ebiosci
san
diego
ca
usa
dilut
fluoresc
activ
cell
sort
fac
buffer
vv
fc
vv
nan
pb
intracellular
gag
stain
cell
permeabil
use
cytofixcytoperm
bd
bioscienc
san
jose
ca
usa
gag
detect
stain
fitclabel
antica
mab
beckman
coulter
brea
ca
usa
dilut
permwash
buffer
bd
bioscienc
detect
total
b
molecul
cell
incub
hybridoma
cell
cultur
supernat
contain
mab
follow
stain
secondari
alexa
antimous
ab
invitrogen
waltham
usa
flow
cytometri
perform
facscalibur
use
cellquest
softwar
bd
bioscienc
data
analyz
use
fac
express
softwar
de
novo
softwar
hela
tzmbl
indic
cell
seed
plate
duplic
cellswel
infect
next
day
ng
vesicular
stomat
virusglycoprotein
vsvg
pseudotyp
virion
standard
content
elisa
aalto
bio
reagent
overnight
incub
fresh
medium
ad
h
later
cell
wash
pb
infect
detect
use
galscreen
chemiluminesc
report
gene
assay
system
appli
biosystem
waltham
usa
activ
quantifi
rel
light
unit
per
second
use
synergi
ht
micropl
reader
data
analysi
softwar
biotek
winooski
vt
usa
infect
hla
cultur
cell
incub
overnight
viru
prepar
equival
ng
cell
cultur
supernat
collect
everi
second
third
day
post
infect
indic
cell
treat
differ
concentr
di
part
medium
chang
delin
day
post
infect
dpi
viru
replic
assess
quantif
virusassoci
revers
transcriptas
activ
p
thymidin
triphosph
ttp
incorpor
use
oligo
dt
poli
templat
describ
elsewher
determin
replic
capac
follow
infect
field
isol
respect
replic
profil
depict
diagram
yaxi
rt
activ
xaxi
dpi
calcul
arithmet
mean
valu
obtain
experi
perform
hlac
differ
donor
area
curv
replic
profil
calcul
defin
correspond
replic
capac
everi
experi
replic
capac
untreat
wt
set
compar
inhibitor
treat
sampl
viabil
infect
treat
cell
assess
watersolubl
tetrazolium
salt
wst
assay
roch
accord
manufactur
instruct
dubinhibitor
impair
gag
process
without
affect
proteas
activ
order
investig
whether
dub
activ
play
role
late
step
replic
analyz
vlp
releas
gag
process
di
treatment
purpos
hela
cell
transient
transfect
express
plasmid
direct
effici
express
protein
except
env
glycoprotein
cell
treat
follow
di
specif
inhibit
dub
di
inhibit
di
addit
inhibit
dub
josephin
domain
contain
deneddylas
western
blot
analys
whole
cell
lysat
vlp
fraction
use
gagspecif
antibodi
reveal
treatment
led
overal
defect
gag
process
promin
accumul
gag
precursor
protein
well
process
intermedi
macanc
maca
vlp
fraction
figur
contrast
addit
di
select
influenc
gag
process
figur
densitometr
analys
western
blot
data
illustr
efficaci
gag
process
reduc
cell
treat
wherea
cell
treat
di
wt
level
figur
indic
certain
dub
activ
regul
late
step
hiv
replic
although
di
clearli
reduc
gag
process
none
inhibitor
influenc
effici
vlp
releas
figur
viru
releas
remain
unaffect
one
explan
defect
gag
process
would
direct
inhibit
pr
di
test
hypothesi
analyz
effect
di
vitro
process
gag
purifi
vlp
deriv
pr
construct
encod
proteas
defici
mutant
viru
lyse
incub
pr
effect
proteas
activ
observ
contrast
addit
di
select
influenc
gag
process
figur
densitometr
analys
western
blot
data
illustr
efficaci
gag
process
reduc
cell
treat
wherea
cell
treat
di
wt
level
figur
indic
certain
dub
activ
regul
late
step
hiv
replic
although
di
clearli
reduc
gag
process
none
inhibitor
influenc
effici
vlp
releas
figur
treatment
led
reduc
gag
process
also
reduc
viru
infect
next
determin
impact
di
infect
releas
viru
particl
perform
singl
round
infect
gener
vesicular
stomat
viru
glycoprotein
vsvg
pseudotyp
vlp
transfect
cell
either
treatment
led
reduc
gag
process
also
reduc
viru
infect
next
determin
impact
di
infect
releas
viru
particl
perform
singl
round
infect
gener
vesicular
stomat
virusglycoprotein
vsvg
pseudotyp
vlp
transfect
cell
either
incub
di
left
untreat
vlp
isol
subsequ
use
singl
round
infect
tzmbl
cell
infect
ascertain
measur
activ
treatment
reduc
infect
releas
vlp
respect
figur
similarli
infect
vlp
gener
treatment
even
diminish
thu
vlp
produc
dub
inhibit
exhibit
loss
specif
infect
like
due
impair
gag
process
analyz
potenti
antiretrovir
activ
di
hlac
prepar
human
tonsil
tissu
infect
hla
cultur
reflect
natur
cell
popul
lymphoid
tissu
support
product
replic
independ
coreceptor
tropism
without
exogen
stimul
cell
infect
either
tcell
macrophag
tropic
standard
equal
amount
follow
perman
day
post
infect
structur
treatment
day
post
infect
increas
concentr
di
cell
cultur
supernat
collect
indic
day
post
infect
dpi
analyz
releas
viru
particl
measur
viru
associ
revers
transcriptas
rt
activ
figur
perman
treatment
di
interf
viru
replic
dosedepend
manner
result
complet
loss
replic
capac
figur
e
almost
result
observ
follow
structur
treatment
indic
sever
block
spread
infect
caus
di
treatment
figur
delay
peak
viru
replic
observ
indic
inhibitori
effect
must
set
immedi
applic
drug
analyz
potenti
antiretrovir
activ
di
hlac
prepar
human
tonsil
tissu
infect
hla
cultur
reflect
natur
cell
popul
lymphoid
tissu
support
product
replic
independ
coreceptor
tropism
without
exogen
stimul
sinc
replic
hlac
gener
exhibit
donordepend
differ
area
curv
auc
repres
replic
capac
hla
cultur
determin
enabl
comparison
result
obtain
hlac
differ
donor
figur
b
e
g
h
j
k
evalu
replic
profil
untreat
wt
compar
structur
treatment
hlac
reveal
concentrationdepend
reduct
replic
capac
set
irrespect
treatment
scheme
tropism
figur
b
g
h
even
dramat
effect
viru
replic
observ
perman
treatment
figur
e
figur
k
irrespect
treatment
scheme
highest
inhibitor
concentr
almost
complet
block
replic
capac
virus
contrast
di
impact
gag
process
effici
reduc
viru
replic
data
shown
exclud
unspecif
effect
cell
viabil
watersolubl
tetrazolium
salt
wst
assay
perform
structur
treatment
inhibitor
concentr
complet
suppress
viru
replic
impact
cell
viabil
figur
perman
treatment
mere
led
slight
stepwis
declin
cell
viabil
highest
concentr
figur
l
altogeth
result
demonstr
di
induc
concentrationdepend
declin
replic
capac
independ
tropism
treatment
scheme
without
show
toxic
effect
sinc
replic
hlac
gener
exhibit
donordepend
differ
area
curv
auc
repres
replic
capac
hla
cultur
determin
enabl
comparison
result
obtain
hlac
differ
donor
figur
b
e
g
h
j
k
evalu
replic
profil
untreat
wt
compar
structur
treatment
hlac
reveal
concentrationdepend
reduct
replic
capac
set
irrespect
treatment
scheme
tropism
figur
b
g
h
even
dramat
effect
viru
replic
observ
perman
treatment
figur
e
figur
k
irrespect
treatment
scheme
highest
inhibitor
concentr
almost
complet
block
replic
capac
virus
contrast
di
impact
gag
process
effici
reduc
viru
replic
data
shown
exclud
unspecif
effect
cell
viabil
watersolubl
tetrazolium
salt
wst
assay
perform
structur
treatment
inhibitor
concentr
complet
suppress
viru
replic
impact
cell
viabil
figur
perman
treatment
mere
led
slight
stepwis
declin
cell
viabil
highest
concentr
figur
l
altogeth
result
demonstr
di
induc
concentrationdepend
declin
replic
capac
independ
tropism
treatment
scheme
without
show
toxic
effect
demonstr
antiretrovir
effect
di
cell
cultur
adapt
molecular
clone
examin
whether
di
also
affect
field
isol
like
multidrug
resist
field
isol
isol
exhibit
sever
drug
resist
mutat
within
rt
pr
open
read
frame
caus
resist
nucleosid
revers
transcriptas
inhibitor
nrti
pr
inhibitor
figur
analyz
influenc
di
replic
capac
hlac
infect
viru
prepar
standard
structur
perman
treatment
indic
amount
appli
figur
measur
viru
associ
rt
activ
show
di
induc
dosedepend
reduct
replic
capac
multidrug
resist
field
isol
observ
demonstr
antiretrovir
effect
di
cell
cultur
adapt
molecular
clone
examin
whether
di
also
affect
field
isol
like
multidrug
resist
field
isol
isol
exhibit
sever
drug
resist
mutat
within
rt
pr
open
read
frame
caus
resist
nucleosid
revers
transcriptas
inhibitor
nrti
pr
inhibitor
figur
analyz
influenc
di
replic
capac
hlac
infect
viru
prepar
standard
structur
perman
treatment
indic
amount
appli
figur
measur
viru
associ
rt
activ
show
di
induc
dosedepend
reduct
replic
capac
multidrug
resist
field
isol
observ
previous
demonstr
proteasom
inhibitor
interfer
gag
process
viru
infect
moreov
shown
proteasom
inhibitor
block
replic
capac
cell
cultur
inhibitor
proteasom
inhibitor
di
induc
accumul
polyubiquitin
protein
albeit
differ
mode
action
thu
intrigu
investig
whether
proteasom
inhibitor
combin
di
would
gener
synergist
effect
replic
capac
therefor
hlac
infect
replic
studi
perform
describ
see
figur
follow
perman
treatment
increas
amount
togeth
nm
proteasom
inhibitor
bortezomib
specif
constitut
proteasom
signific
reduct
replic
capac
observ
figur
c
similar
result
obtain
perman
treatment
increas
amount
nm
specif
inhibitor
immunoproteasom
figur
g
contrast
individu
treatment
di
proteasom
inhibitor
alon
influenc
viru
replic
concentr
rang
cell
viabil
assess
assay
show
appli
substanc
impact
cell
viabil
individu
combinatori
treatment
scheme
figur
f
h
togeth
result
reveal
synergist
antiretrovir
activ
inhibitor
act
compon
up
proteasom
dub
previous
demonstr
proteasom
inhibitor
interfer
gag
process
viru
infect
moreov
shown
proteasom
inhibitor
block
replic
capac
cell
cultur
inhibitor
proteasom
inhibitor
di
induc
accumul
polyubiquitin
protein
albeit
differ
mode
action
thu
intrigu
investig
whether
proteasom
inhibitor
combin
di
would
gener
synergist
effect
replic
capac
therefor
hlac
infect
replic
studi
perform
describ
see
figur
follow
perman
treatment
increas
amount
togeth
nm
proteasom
inhibitor
bortezomib
specif
constitut
proteasom
signific
reduct
replic
capac
observ
figur
c
similar
result
obtain
perman
treatment
increas
amount
nm
specif
inhibitor
immunoproteasom
figur
g
contrast
individu
treatment
di
proteasom
inhibitor
alon
influenc
viru
replic
concentr
rang
cell
viabil
assess
assay
show
appli
substanc
impact
cell
viabil
individu
combinatori
treatment
scheme
figur
f
h
togeth
result
reveal
synergist
antiretrovir
activ
inhibitor
act
compon
up
proteasom
dub
block
deubiquitin
gag
di
also
increas
steadi
state
level
polyubiquitin
gag
thu
entri
up
address
issu
hela
cell
cotransfect
hatag
ubiquitin
haub
syngag
express
plasmid
treat
h
indic
concentr
di
mutant
shown
display
elev
level
ubiquitin
gag
assess
parallel
avoid
rapid
proteasom
degrad
polyubiquitin
gag
speci
follow
di
treatment
cell
incub
proteasom
inhibitor
lactacystin
lc
h
prior
cell
lysi
immunoprecipit
gagspecif
antibodi
western
blot
analys
perform
ubiquitin
gag
speci
detect
antiha
stain
figur
follow
coexpress
syngag
wt
haub
faint
pattern
high
molecular
weight
speci
observ
like
repres
polyubiquitin
gag
upon
treatment
intens
haubsign
clearli
increas
exceed
even
ubiquitinationlevel
mutant
similar
amount
precipit
gag
confirm
antica
stain
thu
treatment
enhanc
polyubiquitin
gag
block
deubiquitin
gag
di
also
increas
steadi
state
level
polyubiquitin
gag
thu
entri
up
address
issu
hela
cell
cotransfect
hatag
ubiquitin
haub
syngag
express
plasmid
treat
h
indic
concentr
di
mutant
shown
display
elev
level
ubiquitin
gag
assess
parallel
avoid
rapid
proteasom
degrad
polyubiquitin
gag
speci
follow
di
treatment
cell
incub
proteasom
inhibitor
lactacystin
lc
h
prior
cell
lysi
immunoprecipit
gagspecif
antibodi
western
blot
analys
perform
ubiquitin
gag
speci
detect
antiha
stain
figur
follow
coexpress
syngag
wt
haub
faint
pattern
high
molecular
weight
speci
observ
like
repres
polyubiquitin
gag
upon
treatment
intens
haubsign
clearli
increas
exceed
even
ubiquitinationlevel
mutant
similar
amount
precipit
gag
confirm
antica
stain
thu
treatment
enhanc
polyubiquitin
gag
previou
studi
demonstr
measur
present
gagderiv
epitop
mhci
molecul
cell
surfac
repres
highli
sensit
reliabl
approach
follow
entri
gag
up
investig
whether
di
treatment
lead
enhanc
antigen
present
measur
present
gagderiv
epitop
mhci
molecul
cell
surfac
describ
previous
transfect
syngagsl
express
plasmid
hela
cell
stabli
express
murin
mhci
allotyp
b
refer
helak
b
cell
flow
cytometri
analys
reveal
concentrationdepend
increas
sl
present
treatment
figur
addit
led
increas
sl
present
addit
caus
even
increas
sl
present
exclud
enhanc
antigen
present
due
elev
level
b
complex
cell
surfac
result
di
treatment
amount
total
b
quantifi
show
similar
amount
b
molecul
cell
surfac
treatment
compar
untreat
control
figur
previou
studi
demonstr
measur
present
gagderiv
epitop
mhci
molecul
cell
surfac
repres
highli
sensit
reliabl
approach
follow
entri
gag
up
investig
whether
di
treatment
lead
enhanc
antigen
present
measur
present
gagderiv
epitop
mhci
molecul
cell
surfac
describ
previous
transfect
syngagsl
express
plasmid
hela
cell
stabli
express
murin
mhci
allotyp
b
refer
helak
b
cell
flow
cytometri
analys
reveal
concentrationdepend
increas
sl
present
treatment
figur
addit
led
increas
sl
present
addit
caus
even
increas
sl
present
exclud
enhanc
antigen
present
due
elev
level
b
complex
cell
surfac
result
di
treatment
amount
total
b
quantifi
show
similar
amount
b
molecul
cell
surfac
treatment
compar
untreat
control
figur
taken
togeth
result
indic
di
especi
target
inhibit
replic
also
lead
enhanc
polyubiquitin
thu
entri
gag
mhci
pathway
commonli
accept
ubiquitin
play
import
role
retroviru
bud
mode
function
particularli
late
replic
step
controversi
discuss
although
studi
suggest
monoubiquitin
gag
contribut
effici
viru
particl
releas
via
endosom
sort
complex
requir
transport
escrt
recent
studi
indic
ubiquitin
gag
occur
independ
escrtcomplex
might
dispens
drive
viral
particl
releas
moreov
demonstr
mutat
ptapmotif
within
caus
enhanc
ubiquitin
gag
due
prolong
membran
associ
process
ascrib
interact
gag
complex
consist
ligas
plasma
membran
addit
shown
recent
highli
conserv
glutam
acid
within
regul
associ
gag
membran
thu
entri
up
mhci
pathway
mutat
motif
lead
prolong
membran
associ
gag
thu
enhanc
entri
up
observ
led
us
specul
wt
situat
certain
dub
interact
domain
gag
remov
polyubiquitin
chain
therebi
regul
entri
up
studi
could
show
di
especi
inhibit
enhanc
entri
gag
up
thu
mhci
pathway
indic
specif
dub
play
import
role
regul
gag
ubiquitin
moreov
gag
process
impair
upon
di
treatment
result
reduc
infect
replic
capac
boost
combinatori
treatment
proteasom
inhibitor
role
vast
varieti
dub
replic
cycl
virus
poorli
understood
although
increas
evid
besid
hiv
also
viru
famili
evolv
strategi
hijack
up
order
accomplish
replic
success
taken
togeth
result
indic
di
especi
target
inhibit
replic
also
lead
enhanc
polyubiquitin
thu
entri
gag
mhci
pathway
commonli
accept
ubiquitin
play
import
role
retroviru
bud
mode
function
particularli
late
replic
step
controversi
discuss
although
studi
suggest
monoubiquitin
gag
contribut
effici
viru
particl
releas
via
endosom
sort
complex
requir
transport
escrt
recent
studi
indic
ubiquitin
gag
occur
independ
escrtcomplex
might
dispens
drive
viral
particl
releas
moreov
demonstr
mutat
ptapmotif
within
caus
enhanc
ubiquitin
gag
due
prolong
membran
associ
process
ascrib
interact
gag
complex
consist
ligas
plasma
membran
addit
shown
recent
highli
conserv
glutam
acid
within
regul
associ
gag
membran
thu
entri
up
mhci
pathway
mutat
motif
lead
prolong
membran
associ
gag
thu
enhanc
entri
up
observ
led
us
specul
wt
situat
certain
dub
interact
domain
gag
remov
polyubiquitin
chain
therebi
regul
entri
up
studi
could
show
di
especi
inhibit
enhanc
entri
gag
up
thu
mhci
pathway
indic
specif
dub
play
import
role
regul
gag
ubiquitin
moreov
gag
process
impair
upon
di
treatment
result
reduc
infect
replic
capac
boost
combinatori
treatment
proteasom
inhibitor
role
vast
varieti
dub
replic
cycl
virus
poorli
understood
although
increas
evid
besid
hiv
also
viru
famili
evolv
strategi
hijack
up
order
accomplish
replic
success
instanc
could
shown
ubligas
well
proteasom
play
import
role
variou
step
viru
replic
eg
entri
matur
latent
viru
reactiv
regard
role
dub
replic
shown
escrtiii
interact
dub
amsh
associ
molecul
domain
stam
inhibit
viral
particl
product
amsh
knockdown
influenc
viru
releas
interestingli
amsh
report
bind
escrtiii
compon
upon
coexpress
act
inhibitor
releas
recent
select
di
becom
avail
facilit
investig
role
dub
viral
replic
di
allow
select
target
one
known
dub
might
one
explan
rel
low
toxic
howev
antiretrovir
activ
di
report
herein
first
time
despit
tremend
effort
made
improv
classic
combin
antiretrovir
therapi
cart
mainli
block
mutationpron
viral
target
increas
risk
treatment
failur
result
drug
resist
incompli
advers
effect
still
great
medic
need
continu
develop
novel
antiretrovir
drug
focu
current
cellular
target
genet
million
time
stabl
thu
harbor
much
lower
risk
drug
resist
small
molecul
affect
cellular
target
offer
treatment
altern
interrupt
cart
case
drug
intoler
develop
multiresist
variant
studi
could
provid
first
evid
di
block
replic
cell
cultur
adapt
molecular
clone
also
multiresist
field
isol
possess
resist
nrti
proteas
inhibitor
use
cart
moreov
could
demonstr
structur
treatment
di
day
post
infect
complet
block
spread
infect
similar
efficaci
perman
treatment
without
affect
cell
viabil
indic
complet
comprehens
block
product
progeni
virus
occur
earli
spread
infect
cell
cultur
must
achiev
di
treatment
effici
enabl
erad
viru
replic
one
explan
observ
might
reduc
infect
virion
releas
di
treatment
like
due
impair
gag
process
howev
addit
impact
di
genom
rna
packag
incorpor
env
glycoprotein
bud
virion
well
activ
regulatori
protein
like
tat
rev
vif
might
also
account
phenomenon
di
share
cellular
target
name
specif
di
exhibit
antiretrovir
activ
indic
alon
togeth
might
play
major
role
replic
shown
previous
specif
cleavag
polyubiquitin
chain
thu
prevent
proteasom
degrad
substrat
could
show
treatment
di
target
lead
enhanc
polyubiquitin
entri
gag
mhci
pathway
indic
somehow
interact
gag
prevent
entri
up
shown
previous
inhibit
proteasom
lead
accumul
polyubiquitin
gag
speci
interfer
gagprocess
later
shown
proteasom
inhibitor
interfer
replic
human
peripher
blood
mononuclear
cell
pbmc
studi
could
show
addit
di
lead
accumul
polyubiquitin
gag
speci
reduct
gagprocess
thu
specul
combinatori
treatment
hlac
di
proteasom
inhibitor
might
synergist
inhibit
viru
replic
si
et
al
previous
shown
di
boost
inhibitori
effect
proteasom
inhibitor
coxsacki
viru
replic
howev
case
di
alon
effect
replic
coxsacki
viru
supraaddit
effect
detect
even
inhibitor
ad
high
concentr
possibl
inhibitor
proteasom
inhibitor
di
necessari
virus
effici
reduc
pool
free
ub
shown
necessari
block
coxsacki
viru
replic
contrari
data
illustr
di
enhanc
effect
proteasom
inhibitor
inhibit
replic
low
supraeffect
concentr
level
inhibitor
appli
individu
neither
proteasom
inhibitor
di
influenc
replic
low
concentr
thu
result
suggest
inhibitor
di
proteasom
inhibitor
induc
synergist
effect
without
affect
cell
viabil
mainli
two
possibl
explan
synergist
effect
di
proteasom
inhibitor
first
amount
free
ubiquitin
significantli
reduc
accumul
polyubiquitin
protein
lack
recycl
polyubiquitin
chain
might
interfer
function
escrtcomplex
earli
act
escrt
factor
like
escrti
escrtii
interact
protein
x
alix
possess
ubiquitin
bind
domain
thu
ubiquitin
may
play
import
role
substrat
recognit
second
addit
di
togeth
proteasom
inhibitor
might
lead
accumul
socal
defect
ribosom
product
drip
drip
de
novo
synthes
erron
protein
rapidli
degrad
via
up
origin
shown
gag
protein
bona
fide
substrat
drippathway
proteasom
inhibitor
lead
accumul
drip
combinatori
treatment
cell
di
might
lead
enhanc
accumul
gagdrip
within
cell
therebi
gagdrip
interfer
viru
releas
disturb
highli
order
assembl
gag
molecul
prionlik
manner
studi
observ
di
caus
gener
gag
process
defect
one
explan
phenomenon
would
di
directli
inhibit
viral
proteas
howev
possibl
could
exclud
vitro
process
assay
reveal
appli
di
even
high
concentr
effect
viral
proteas
anoth
explan
might
polyubiquitin
chain
conjug
gag
steric
disturb
highli
order
lattic
assembl
gag
thu
exert
neg
effect
highli
order
gagassembl
viru
bud
eventu
also
autoactiv
viral
proteas
anoth
possibl
may
direct
mask
viral
proteas
cleavag
site
bulki
polyubiquitin
adduct
accumul
process
intermedi
shown
previous
interfer
viral
infect
transdomin
neg
manner
concert
observ
treatment
di
reduc
viru
infect
dosedepend
manner
polyubiquitin
protein
prerequisit
proteasom
degrad
although
steadi
state
amount
gag
affect
addit
di
mhci
antigen
present
final
consequ
proteasom
degrad
significantli
enhanc
find
concert
previou
studi
show
enhanc
mhci
antigen
present
necessarili
correl
diminish
halflif
gag
possibl
explan
observ
might
minor
fraction
gag
enter
up
follow
treatment
di
reduc
overal
level
gag
remain
nonubiquitin
consist
possibl
notion
fraction
de
novo
synthes
protein
approx
enter
drippathway
numer
studi
show
target
antigen
degrad
proteasom
repres
power
approach
enhanc
mhc
class
antigen
present
induc
effici
cytotox
tcell
ctl
respons
show
also
di
caus
significantli
enhanc
mhc
class
antigen
present
gagderiv
epitop
thu
legitim
specul
di
reduc
viral
replic
might
also
induc
better
ctl
recognit
cell
vivo
overal
data
support
model
wherebi
certain
dub
play
import
role
replic
regul
gag
process
thu
infect
releas
virion
simultan
entri
gag
up
mhci
pathway
